Long‐term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Mifepristone (RU486) is a potent antiprogestagen, and at high doses it also acts as an antiglucocorticoid drug. Mifepristone, administered as a single 600 mg dose, is commonly employed to induce medical abortion in conjunction with prostaglandins. The long‐term safety profile of mifepristone, especially at high doses, is less well‐established. Long‐term mifepristone is considered efficacious in treating uterine myomas, endometriosis (25–100 mg/day), and possibly in inoperable meningiomas (200 mg/day), as well as inoperable Cushing's syndrome. Many animal studies document an antiproliferative effect (antioestrogenic), as do some reports in humans. However, there are also data to suggest that, as an antiprogestagen, mifepristone may promote an unopposed oestrogen milieu, and thus have a proliferative effect upon the endometrium. We hereby describe the first reported case of an adolescent female with Cushingoid features and morbid osteoporosis who was treated with mifepristone for its antiglucocorticoid effect (400 mg/day) in an attempt to prevent further bone loss. The patient's striae, weight gain, and buffalo hump markedly improved, and further bone loss was halted. However, with each of the two 6‐month courses of mifepristone (9 months apart) she developed massive simple endometrial hyperplasia and a markedly enlarged uterus. This reversed to normal after cessation of mifepristone treatment. In conclusion, High doses of the antiprogestagen mifepristone over a prolonged period of time may promote an unopposed oestrogen milieu leading to endometrial hyperplasia. Therefore, interval pelvic imaging in women who receive long‐term mifepristone may be prudent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58022-4 · Cited by 216
Cited by
Physiology of the Endometrium and Regulation of Menstruation
Critchley, H. O. D., Maybin, J. A., Armstrong, G. M., & Williams, A. R. W. (2020) · Physiological Reviews · doi:10.1152/physrev.00031.2019 · Cited by 536
Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
Chabbert-Buffet, N., Meduri, G., Bouchard, P., & Spitz, I. M. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi002 · Cited by 310
Self-citationLobo, R. A. (2007) · Comprehensive Gynecology · doi:10.1016/b978-0-323-02951-3.50022-4 · Cited by 4
Metadata
- Authors
- Newfield, R. S., Spitz, I. M., Isacson, C., & New, M. I.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 54
- Issue
- 3
- Pages
- 399-404
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2079241337
- Cited by
- 81
- References
- 1
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01026.x
- The paper
- Newfield, R. S., Spitz, I. M., Isacson, C., & New, M. I. (2001). Long‐term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01026.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.